Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Milan - Delayed Quote EUR

BIOMARIN PHARMACEUTICAL (1BMRN.MI)

Compare
65.64
+0.44
+(0.67%)
At close: March 5 at 3:48:53 PM GMT+1
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
2,853,915
2,853,915
2,419,226
2,096,039
1,846,275
Cost of Revenue
580,235
580,235
532,062
503,023
470,515
Gross Profit
2,273,680
2,273,680
1,887,164
1,593,016
1,375,760
Operating Expense
1,799,484
1,799,484
1,701,373
1,535,606
1,450,093
Operating Income
474,196
474,196
185,791
57,410
-74,333
Net Non Operating Interest Income Expense
62,153
62,153
43,921
3,627
-4,855
Other Income Expense
5,332
5,332
-38,215
90,138
3,846
Pretax Income
541,763
541,763
188,563
149,576
-75,350
Tax Provision
114,904
114,904
20,918
8,015
-11,270
Net Income Common Stockholders
426,859
426,859
167,645
141,561
-64,080
Average Dilution Earnings
7,327
7,327
--
--
--
Diluted NI Available to Com Stockholders
434,186
434,186
167,645
141,561
-64,080
Basic EPS
2.25
2.25
0.89
0.76
-0.35
Diluted EPS
2.21
2.21
0.87
0.75
-0.35
Basic Average Shares
190,027
190,027
187,834
185,266
182,852
Diluted Average Shares
196,708
196,708
191,595
188,963
182,852
Total Operating Income as Reported
484,214
484,214
185,774
160,974
-82,341
Total Expenses
2,379,719
2,379,719
2,233,435
2,038,629
1,920,608
Net Income from Continuing & Discontinued Operation
426,859
426,859
167,645
141,561
-64,080
Normalized Income
418,979.93
418,979.93
167,645
43,512.39
-57,276.55
Interest Income
74,883
74,883
58,339
18,034
10,482
Interest Expense
12,339
12,339
13,824
13,814
14,744
Net Interest Income
62,153
62,153
43,921
3,627
-4,855
EBIT
554,102
554,102
202,387
163,390
-60,606
EBITDA
650,528
650,528
306,773
265,359
47,433
Reconciled Cost of Revenue
527,109
527,109
489,876
463,854
424,376
Reconciled Depreciation
96,426
96,426
104,386
101,969
108,039
Net Income from Continuing Operation Net Minority Interest
426,859
426,859
167,645
141,561
-64,080
Total Unusual Items Excluding Goodwill
10,000
10,000
--
103,600
-8,000
Total Unusual Items
10,000
10,000
--
103,600
-8,000
Normalized EBITDA
640,528
640,528
306,773
161,759
55,433
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
2,120.93
2,120.93
--
5,551.39
-1,196.55
12/31/2021 - 1/3/2024

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

1MRNA.MI Moderna, Inc.
31.98
+7.51%
 
TRDA Entrada Therapeutics, Inc.
10.42
-1.51%
 
IPSC Century Therapeutics, Inc.
0.6550
+7.80%
 
ERAS Erasca, Inc.
1.4200
0.00%
 
NEXI NexImmune, Inc.
0.0001
-99.93%
 
LPTX Leap Therapeutics, Inc.
0.4403
+2.61%
 
LYRA Lyra Therapeutics, Inc.
0.1882
+0.97%
 
BPTH Bio-Path Holdings, Inc.
0.1725
-0.23%
 
AIM AIM ImmunoTech Inc.
0.1343
+2.13%
 
FDMT 4D Molecular Therapeutics, Inc.
4.1400
-0.48%